XNAS · Healthcare · Biotechnology
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | -0.05 | -0.09 | -80.00% | $105.4M | ❌ Miss | -4.84% | -10.26% | — |
| 2026-02-25 | Q4 2025 | 0.07 | 0.13 | +85.71% | $129.5M | ✅ Beat | +7.37% | -10.70% | -21.44% |
| 2025-10-28 |
| Q3 2025 |
| -0.10 |
| 0.06 |
| +160.00% |
| $99.2M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | -0.16 | -0.13 | +18.75% | $81.5M | ✅ Beat | +2.21% | +1.76% | +11.65% |
| 2025-02-25 | Q4 2024 | -0.27 | -0.09 | +66.67% | $71.4M | ✅ Beat | +8.36% | +9.84% | +31.89% |
| 2024-11-06 | Q3 2024 | -0.42 | -0.33 | +21.43% | $44.8M | ✅ Beat | +7.66% | +8.39% | +28.36% |
| 2024-08-14 | Q2 2024 | -0.57 | -0.42 | +26.32% | $30.9M | ✅ Beat | -11.27% | -12.94% | +11.27% |
| 2024-05-14 | Q1 2024 | -0.73 | -0.32 | +56.16% | $49.6M | ✅ Beat | +13.65% | +16.61% | +14.88% |
Showing last 8 quarters.